Copyright
©2014 Baishideng Publishing Group Inc.
World J Clin Urol. Nov 24, 2014; 3(3): 264-271
Published online Nov 24, 2014. doi: 10.5410/wjcu.v3.i3.264
Published online Nov 24, 2014. doi: 10.5410/wjcu.v3.i3.264
Figure 1 Schematic view of the therapeutic medicines targeting androgen receptor signaling pathways.
ACTH: Adrenocorticotropic hormone; AR: Androgen receptor; ARE: Androgen response element; LH: Luteinizing hormone; LHRH: Luteinizing hormone-releasing hormone; DHT: Dihydrotestosterone; CYP: Cytochrome P450.
- Citation: Obinata D, Fujiwara K, Yamaguchi K, Takayama KI, Urano T, Nagase H, Inoue S, Takahashi S, Fukuda N. Review of novel therapeutic medicines targeting androgen signaling in castration-resistant prostate cancer. World J Clin Urol 2014; 3(3): 264-271
- URL: https://www.wjgnet.com/2219-2816/full/v3/i3/264.htm
- DOI: https://dx.doi.org/10.5410/wjcu.v3.i3.264